Microbot Medical Inc. MBOT
Microbot Medical Inc. (Nasdaq: MBOT) is a cardio-renal-metabolic medical device company. Its next catalyst on record is LIBERTY Endovascular Robotic System: CE Mark approval (EU MDR) (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: LIBERTY Endovascular Robotic System — CE Mark approval (EU MDR) (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LIBERTY Endovascular Robotic System | Peripheral endovascular interventions (510(k) cleared Sept 2025; full US market release April 2026) | device-combination | NA_NON_THERAPEUTIC |
| NovaCross (NovaCross Xtreme, NovaCross BTK) | Intraluminal revascularization devices with integrated microcatheter (acquired from Nitiloop) | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other cardio-renal-metabolic companies
- DexCom, Inc. DXCM
- Penumbra Inc PEN
- Insulet Corp PODD
- MiniMed Group, Inc. MMED
- Heartflow, Inc. HTFL
- iRhythm Holdings, Inc. IRTC
- Pulse Biosciences, Inc. PLSE
- AtriCure, Inc. ATRC
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.